Osteoporosis, Postmenopausal study: Romosozumab vs Teriparatide
Official title Combined Anabolic Therapy
ClinicalTrials.gov ID: NCT06558188
What this study is testing
What is Romosozumab?
An investigational once‑monthly injectable medicine being studied for postmenopausal osteoporosis. is designed to inhibit sclerostin, a protein that regulates bone formation and resorption.
Also referred to as Evenity.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study aims to learn how two different treatment plans affect bone health in women after menopause.
- Who it's for
- Postmenopausal women who have been diagnosed with osteoporosis.
- What's involved
- Participants will receive one of two medication regimens and attend scheduled visits for health checks and tests.
- Phase 4: studies an already-approved treatment
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 45 and older, women only. Healthy volunteers may be eligible.
You may be able to join if
- women aged 45+
- postmenopausal
- osteoporotic with high risk of fracture
You likely can't join if
- no significant previous use of bone health modifying treatments
- known congenital or acquired bone disease other than osteoporosis
- significant renal disease, liver disease, cardiopulmonary disease, or psychiatric disease
- abnormal calcium or parathyroid hormone level
- serum vitamin D \<20 ng/dL
- anemia (hematocrit \<32%)
See the full eligibility criteria
- women aged 45+
- postmenopausal
- osteoporotic with high risk of fracture
- no significant previous use of bone health modifying treatments
- known congenital or acquired bone disease other than osteoporosis
- significant renal disease, liver disease, cardiopulmonary disease, or psychiatric disease
- abnormal calcium or parathyroid hormone level
- serum vitamin D \<20 ng/dL
- anemia (hematocrit \<32%)
- history of malignancy (except non-melanoma skin carcinoma)
- excessive alcohol use or substance abuse
- known contraindications to romosozumab or teriparatide
The study team makes the final eligibility decision.
Where it is enrolling
- Boston, Massachusetts, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling female, 45 years and older. Healthy volunteers may be eligible. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Boston, Massachusetts, United States. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.